Skip to main content

Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors

Hedge fund managers sit on the boards of Bausch Health and Bausch + Lomb. They don’t think like your typical corporate board, writes Ken Squire of 13D Monitor.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.